Astrana Health [ASTH] vs Pacs [PACS] Detailed Stock Comparison
Astrana Health
NASDAQ
Loading...
Pacs
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Astrana Health wins in 11 metrics, Pacs wins in 7 metrics, with 0 ties. Astrana Health appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Astrana Health | Pacs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 56.49 | 19.41 | Pacs |
| Price-to-Book Ratio | 1.92 | 3.15 | Astrana Health |
| Debt-to-Equity Ratio | 83.20 | 469.36 | Astrana Health |
| PEG Ratio | -1.08 | 6.61 | Astrana Health |
| EV/EBITDA | 13.84 | 17.61 | Astrana Health |
| Profit Margin (TTM) | 1.04% | 2.59% | Pacs |
| Operating Margin (TTM) | 3.11% | 0.07% | Astrana Health |
| EBITDA Margin (TTM) | 3.11% | 0.07% | Astrana Health |
| Return on Equity | 5.44% | 110.96% | Pacs |
| Return on Assets (TTM) | 3.25% | 3.21% | Astrana Health |
| Free Cash Flow (TTM) | $44.17M | $-109.11M | Astrana Health |
| 1-Year Return | -37.72% | -71.61% | Astrana Health |
| Price-to-Sales Ratio (TTM) | 0.57 | 0.52 | Pacs |
| Enterprise Value | $1.37B | $4.39B | Pacs |
| EV/Revenue Ratio | 0.57 | 1.23 | Astrana Health |
| Gross Profit Margin (TTM) | 11.91% | 15.67% | Pacs |
| Revenue per Share (TTM) | $50 | $27 | Astrana Health |
| Earnings per Share (Diluted) | $0.53 | $0.61 | Pacs |
| Beta (Stock Volatility) | 0.86 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Astrana Health vs Pacs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Astrana Health | 2.37% | 1.46% | 30.08% | 18.98% | -16.00% | -6.93% |
| Pacs | 2.73% | 1.73% | 0.95% | 18.72% | -8.29% | -9.28% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Astrana Health | -37.72% | -30.63% | 64.85% | 252.59% | 487.65% | 487.65% |
| Pacs | -71.61% | -51.13% | -51.13% | -51.13% | -51.13% | -51.13% |
Performance & Financial Health Analysis: Astrana Health vs Pacs
| Metric | ASTH | PACS |
|---|---|---|
| Market Information | ||
| Market Cap | $1.38B | $1.84B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 632,930 | 403,171 |
| 90 Day Avg. Volume | 438,513 | 479,024 |
| Last Close | $30.68 | $12.05 |
| 52 Week Range | $21.20 - $63.20 | $8.28 - $43.92 |
| % from 52W High | -51.46% | -72.56% |
| All-Time High | $133.23 (Nov 15, 2021) | $43.92 (Oct 28, 2024) |
| % from All-Time High | -76.97% | -72.56% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.35% | 0.29% |
| Quarterly Earnings Growth | -0.51% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.01% | 0.03% |
| Operating Margin (TTM) | 0.03% | 0.00% |
| Return on Equity (TTM) | 0.05% | 1.11% |
| Debt to Equity (MRQ) | 83.20 | 469.36 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $15.58 | $3.75 |
| Cash per Share (MRQ) | $6.85 | $0.48 |
| Operating Cash Flow (TTM) | $130.56M | $99.09M |
| Levered Free Cash Flow (TTM) | $97.63M | $1.62B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Astrana Health vs Pacs
| Metric | ASTH | PACS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 56.49 | 19.41 |
| Forward P/E | 19.57 | 6.61 |
| PEG Ratio | -1.08 | 6.61 |
| Price to Sales (TTM) | 0.57 | 0.52 |
| Price to Book (MRQ) | 1.92 | 3.15 |
| Market Capitalization | ||
| Market Capitalization | $1.38B | $1.84B |
| Enterprise Value | $1.37B | $4.39B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.57 | 1.23 |
| Enterprise to EBITDA | 13.84 | 17.61 |
| Risk & Other Metrics | ||
| Beta | 0.86 | N/A |
| Book Value per Share (MRQ) | $15.58 | $3.75 |
Financial Statements Comparison: Astrana Health vs Pacs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ASTH | PACS |
|---|---|---|
| Revenue/Sales | $620.39M | $981.85M |
| Cost of Goods Sold | $549.06M | $827.98M |
| Gross Profit | $71.33M | $153.87M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $20.58M | $710,000 |
| EBITDA | $23.81M | $5.58M |
| Pre-Tax Income | $9.60M | $-12.38M |
| Income Tax | $3.38M | $-1.47M |
| Net Income (Profit) | $6.22M | $-10.91M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ASTH | PACS |
|---|---|---|
| Cash & Equivalents | $258.52M | $73.37M |
| Total Current Assets | $613.27M | $800.65M |
| Total Current Liabilities | $361.27M | $468.10M |
| Long-Term Debt | $433.40M | $2.54B |
| Total Shareholders Equity | $517.71M | $578.23M |
| Retained Earnings | $292.88M | $100.50M |
| Property, Plant & Equipment | $47.55M | $2.15B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ASTH | PACS |
|---|---|---|
| Operating Cash Flow | $12.67M | $-33.46M |
| Capital Expenditures | $-3.07M | $-111.48M |
| Free Cash Flow | $13.56M | $-76.67M |
| Debt Repayment | $-428.38M | $-465.05M |
| Common Stock Repurchase | $-1.32M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ASTH | PACS |
|---|---|---|
| Shares Short | 1.61M | 2.47M |
| Short Ratio | 5.33 | 4.79 |
| Short % of Float | 0.06% | N/A |
| Average Daily Volume (10 Day) | 632,930 | 403,171 |
| Average Daily Volume (90 Day) | 438,513 | 479,024 |
| Shares Outstanding | 47.93M | 147.77M |
| Float Shares | 37.55M | 43.04M |
| % Held by Insiders | 0.22% | 0.72% |
| % Held by Institutions | 0.53% | 0.29% |
Dividend Analysis & Yield Comparison: Astrana Health vs Pacs
| Metric | ASTH | PACS |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |